Wednesday, June 15, 2022 The HE1 study, "Phase III Study of Palliative Radiotherapy for Symptomatic Hepatocellular Carcinoma and Liver Metastases" has closed to accrual. This is a multi-centre, randomized, phase III trial of best supportive care (BSC) with or without single fraction liver radiation therapy (8 Gy) in patients with end-stage, painful, hepatocellular carcinoma or liver metastases. The purpose of this study is to see whether one dose of palliative radiation therapy directed to the liver in combination with standard BSC might help to reduce liver pain/discomfort due to cancer when compared to getting standard BSC alone. For more information please visit the CCTG HE1 trial page.
